Bu-Fei-Huo-Xue capsule alleviates bleomycin-induced pulmonary fibrosis in mice through modulating gut microbiota
Open Access
- 8 February 2023
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14, 1084617
- https://doi.org/10.3389/fphar.2023.1084617
Abstract
Bu-Fei-Huo-Xue capsule (BFHX) has been used to treat pulmonary fibrosis (PF) in clinic. However, the mechanism of BFHX on PF remains unclear. Recent studies have shown that the changes in gut microbiota were closely related to the progression of PF. Modulating gut microbiota provides new thoughts in the treatment of PF. In this study, a mouse model of PF was induced using bleomycin (BLM) and treated with BFHX. We firstly evaluated the therapeutic effects of BFHX on PF model mice. Besides, the anti-inflammatory and anti-oxidative effects of BFHX were evaluated. Furthermore, 16S rRNA sequencing was used to observe the changes in gut microbiota in PF model mice after BFHX treatment. Our results showed that BFHX significantly reduced the collagen deposition in PF model mice. BFHX treatment also reduced the levels of pro-inflammatory cytokines and inhibited the oxidative stress in lung. 16S rRNA sequencing showed that BFHX affected the diversity of gut microbiota and the relative abundances of gut microbiota such as Lactobacillus,Lachnospiraceae_NK4A136_group,and Romboutsia. In conclusion, our study demonstrated the therapeutic effects of BFHX on PF. The mechanisms of BFHX on PF may be associated with regulating gut microbiota.This publication has 35 references indexed in Scilit:
- Combined Signature of the Fecal Microbiome and Metabolome in Patients with GoutFrontiers in Microbiology, 2017
- Traditional Chinese medicine for pulmonary fibrosis therapy: Progress and future prospectsJournal of Ethnopharmacology, 2017
- Nrf2 inhibits epithelial-mesenchymal transition by suppressing snail expression during pulmonary fibrosisScientific Reports, 2016
- Helicobacter pylori Update: Gastric Cancer, Reliable Therapy, and Possible BenefitsGastroenterology, 2015
- Role of the normal gut microbiotaWorld Journal of Gastroenterology, 2015
- Modeling pulmonary fibrosis with bleomycinCurrent Opinion in Pulmonary Medicine, 2011
- The basics of epithelial-mesenchymal transitionJCI Insight, 2009
- The bleomycin animal model: A useful tool to investigate treatment options for idiopathic pulmonary fibrosis?The International Journal of Biochemistry & Cell Biology, 2008
- Mechanisms of Pulmonary FibrosisAnnual Review of Medicine, 2004
- Lung Cytokine Production in Bleomycin-Induced Pulmonary FibrosisExperimental Lung Research, 1992